A Review of Ocular Drug Delivery Platforms and Drugs for Infectious and Noninfectious Uveitis: The Past, Present, and Future

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Aug 28

PMID 34452185

Citations 6

Authors

Christopher D Conrady

Steven Yeh

Affiliations

Soon will be listed here.

Abstract

Uveitis refers to a broad group of inflammatory disorders of the eye that often require medical and surgical management to improve or stabilize vision and prevent vision-threatening pathological changes to the eye. Drug delivery to the eye to combat inflammation and subsequent complications from uveitic conditions is complex as there are multiple barriers to absorption limiting availability of the needed drug in the affected tissues. As such, there has been substantial interest in developing new drugs and drug delivery platforms to help reduce intraocular inflammation and its complications. In this review, we discuss the challenges of drug delivery, novel technologies recently approved for uveitis patient care and promising drug delivery platforms for uveitis and sequelae of ocular inflammation.

Citing Articles

How to Fabricate Hyaluronic Acid for Ocular Drug Delivery.

Kim M, Jung M, Lee D, Ahn S, Lee G, Park C Pharmaceutics. 2025; 16(12.

PMID: 39771582 PMC: 11680071. DOI: 10.3390/pharmaceutics16121604.

Targeting Oxidative Stress and Inflammation in the Eye: Insights from a New Model of Experimental Autoimmune Uveitis.

Chistyakov D, Tiulina V, Gancharova O, Baksheeva V, Goriainov S, Shebardina N Int J Mol Sci. 2024; 25(23).

PMID: 39684616 PMC: 11641703. DOI: 10.3390/ijms252312910.

Ocular mucoadhesive and biodegradable spanlastics loaded cationic spongy insert for enhancing and sustaining the anti-inflammatory effect of prednisolone Na phosphate; Preparation, I-optimal optimization, and In-vivo evaluation.

Said M, Ali K, Alfadhel M, Afzal O, Aldosari B, Alsunbul M Int J Pharm X. 2024; 8:100293.

PMID: 39498272 PMC: 11533070. DOI: 10.1016/j.ijpx.2024.100293.

The Evolution of Triamcinolone Acetonide Therapeutic Use in Retinal Diseases: From Off-Label Intravitreal Injection to Advanced Nano-Drug Delivery Systems.

Aceves-Franco L, Sanchez-Aguilar O, Barragan-Arias A, Ponce-Gallegos M, Navarro-Partida J, Santos A Biomedicines. 2023; 11(7).

PMID: 37509540 PMC: 10377205. DOI: 10.3390/biomedicines11071901.

Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation.

Lage N, Paiva M, Vasconcelos-Santos D, Machado R, Fialho S, Silva-Cunha A Pharmaceutics. 2023; 15(1).

PMID: 36678822 PMC: 9863942. DOI: 10.3390/pharmaceutics15010193.

References

Kempen J, Altaweel M, Holbrook J, Sugar E, Thorne J, Jabs D . Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis. JAMA. 2017; 317(19):1993-2005. PMC: 5540027. DOI: 10.1001/jama.2017.5103. View

Silver P, Silver P, Horai R, Chen J, Jittayasothorn Y, Chan C . Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis. J Immunol. 2015; 194(7):3011-9. PMC: 4459505. DOI: 10.4049/jimmunol.1402650. View

Pelegrin L, de la Maza M, Molins B, Rios J, Adan A . Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis. Eye (Lond). 2015; 29(7):943-50. PMC: 4506349. DOI: 10.1038/eye.2015.73. View

Conrady C, Demirci H, Wubben T . Retinal Whitening After Lung Transplant for Cystic Fibrosis. JAMA Ophthalmol. 2020; 138(9):994-995. DOI: 10.1001/jamaophthalmol.2020.1306. View

Del Amo E, Rimpela A, Heikkinen E, Kari O, Ramsay E, Lajunen T . Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2016; 57:134-185. DOI: 10.1016/j.preteyeres.2016.12.001. View

Morelle G, Gueudry J, Uettwiller F, Wouters C, Bader-Meunier B, Robert M . Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort. RMD Open. 2019; 5(2):e000933. PMC: 6691513. DOI: 10.1136/rmdopen-2019-000933. View

Leal I, Rodrigues F, Sousa D, Romao V, Duarte G, Carreno E . Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review. Acta Ophthalmol. 2018; 96(6):e665-e675. DOI: 10.1111/aos.13699. View

Chen M, Li X, Liu J, Han Y, Cheng L . Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. J Control Release. 2015; 203:109-17. DOI: 10.1016/j.jconrel.2015.02.021. View

Yoon S, Rhee D, Marx J, Blaha G, Rogers A, Baumal C . Anatomic and visual outcomes of noninfectious endophthalmitis after intravitreal triamcinolone. Am J Ophthalmol. 2009; 147(6):1031-6. DOI: 10.1016/j.ajo.2008.12.034. View

10.

Danielescu C, Anton N, Stanca H, Munteanu M . Endogenous Endophthalmitis: A Review of Case Series Published between 2011 and 2020. J Ophthalmol. 2020; 2020:8869590. PMC: 7603614. DOI: 10.1155/2020/8869590. View

11.

Cai C, Skalak C, Keenan R, Grewal D, Jaffe G . Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant. Graefes Arch Clin Exp Ophthalmol. 2020; 258(5):1023-1030. DOI: 10.1007/s00417-020-04614-x. View

12.

Conrady C, Sassalos T, Cornblath W, Zacks D, Johnson M . Temporally independent association of multiple evanescent white dot syndrome and optic neuritis. Graefes Arch Clin Exp Ophthalmol. 2021; 259(9):2807-2811. DOI: 10.1007/s00417-021-05249-2. View

13.

Tse A, Shah M, Jamal N, Shaikh A . Glaucoma treatment adherence at a United Kingdom general practice. Eye (Lond). 2016; 30(8):1118-22. PMC: 4985664. DOI: 10.1038/eye.2016.103. View

14.

Ahmad Z, Hughes B, Abrams G, Mahmoud T . Combined posterior chamber intraocular lens, vitrectomy, Retisert, and pars plana tube in noninfectious uveitis. Arch Ophthalmol. 2012; 130(7):908-13. DOI: 10.1001/archophthalmol.2011.1425. View

15.

Grajewski R, Silver P, Agarwal R, Su S, Chan C, Liou G . Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunity. J Exp Med. 2006; 203(4):851-6. PMC: 2118294. DOI: 10.1084/jem.20050429. View

16.

Brockhaus L, Goldblum D, Eggenschwiler L, Zimmerli S, Marzolini C . Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. Clin Microbiol Infect. 2019; 25(11):1364-1369. DOI: 10.1016/j.cmi.2019.01.017. View

17.

Fabrizio V, Rodriguez-Sanchez M, Mauguen A, Dahi P, Doubrovina E, OReilly R . Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses. Blood Adv. 2021; 5(2):496-503. PMC: 7839363. DOI: 10.1182/bloodadvances.2020002735. View

18.

Bucher K, Rodriguez-Bocanegra E, Dauletbekov D, Fischer M . Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety. Prog Retin Eye Res. 2020; 83:100915. DOI: 10.1016/j.preteyeres.2020.100915. View

19.

Gregoire S, Terrada C, Martin G, Fourcade G, Baeyens A, Marodon G . Treatment of Uveitis by In Situ Administration of Ex Vivo-Activated Polyclonal Regulatory T Cells. J Immunol. 2016; 196(5):2109-18. DOI: 10.4049/jimmunol.1501723. View

20.

Adan A, Pelegrin L, Rey A, Llorenc V, Mesquida M, Molins B . Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina. 2013; 33(7):1435-40. DOI: 10.1097/IAE.0b013e31827e247b. View